Biogen said global TYSABRI revenue decreased $1,715.0 million, or 8.6%, in 2024, TECFIDERA revenue decreased $967.1 million, or 4.5%, and Interferon revenue decreased $968.0 million, or 12.5%.

1. 01

   Biogen said global TYSABRI revenue decreased $1,715.0 million, or 8.6%, in 2024, TECFIDERA revenue decreased $967.1 million, or 4.5%, and Interferon revenue decreased $968.0 million, or 12.5%.

2. 02

   The company said global SKYCLARYS revenue in 2024 was $382.5 million, comprising $301.1 million in the U.S. and $81.4 million in rest of world, with the rest of world revenue generated following E.U. commercialization in Q1 2024.

3. 03

   Biogen said its outstanding long-term debt balance as of December 31, 2024 was $4,547.2 million. It also said that during 2024 it repaid the remaining $150.0 million of the 364-day tranche and $500.0 million of the 3-year tranche of the 2023 Term Loan.

4. 04

   The company said in connection with its acquisition of HI-Bio in July 2024 it may pay up to $650.0 million in additional contingent consideration based on development and regulatory milestones, and the acquisition-date fair value was approximately $485.1 million.

Key figures

Fiscal year ended December 31, 2024

Revenue

$9.7B

Net income

$1.6B

EPS

$11.18

Operating cash flow

$2.9B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.